Abstract A 62-year-old 
Introduction
Aspergillus empyema is a rare and potentially lifethreatening invasive fungal infection (1) . Aspergillus empyema is a complication of aspergilloma and chronic necrotizing pulmonary aspergillosis (CNPA) or surgery for these diseases and responds to treatment slowly (2, 3) . Some cases reported in the literature were treated with standard regimens for invasive pulmonary aspergillosis (IPA) or underwent surgical therapy (4) (5) (6) (7) . Three classes of antifungal drugs are available for treating aspergillosis: polyenes, azoles, and echinocandins (8, 9) . Recently, voriconazole (VRCZ) , an azole antimycotic agent, was recommended as a primary therapeutic agent for invasive aspergillosis (9) . For refractory cases, addition of another drug for salvage therapy has been recommended in the guidelines for treating aspergillosis. Preclinical and clinical data have suggested a synergistic interaction between echinocandins and triazoles against Aspergillus species (10) (11) (12) . In one study, micafungin (MCFG), used in primary or salvage therapy, was proven to be efficacious and safe for high-risk patients with IPA, although the number of patients studied was small (13) . (14) , there are only a few reports describing penetration of antifungal agents into pleural fluid in empyema cases (15, 16 (Figs. 2a, 2b) .
Adequate drug penetration into the infection site is crucial for optimal antimicrobial treatment. Although there are many studies regarding penetration of antibacterial agents into pleural effusion

F i g u r e 1 . Ch e s t X-r a y ( CXR) a t t h e r e g u l a r h o s p i t a l ( A) s h o ws p n e u mo t h o r a x wi t h a i r -f l u i d l e v e l i n t h e l e f t t h o r a c i c c a v i t y ; c h e s t CT ( a ) s h o ws c o l l a p s e o f t h e l e f t l u n g wi t h b u l l a . CXR o n t h e d a y o f a d mi s s i o n t o o u r h o s p i t a l ( B ) s h o ws i n s e r t e d d r a i n a g e t u b e a n d p n e u mo t h o r a x i n t h e l e f t t h or a c i c s p a c e ; c h e s t CT s h o ws c o l l a p s e d l u n g wi t h v i s c e r a l p l e u r a l t h i c k e n i n g a n d p l e u r a l f l u i d i n t h e l e f t t h o r a c i c c a v i t y ( b
F i g u r e 3 . P a t h o l o g i c a l f i n d i n g s h o ws n a r r o w, a c u t e l y b r a n c h i n g s e p t a t e h y p h a e i n n e c r o t i c t i s s u e o n He ma t o x y l i n E o s i n s t a i n i n g a n d Gr o c o t t ' s s t a i n ( a , b ) .
Histopathological examination of a pleural biopsy (Figs. 3a, 3b) (Fig. 4) . When the pleural fluid drainage volume decreased to <50 mL/day, the chest tube was removed; this was on day 43 after VRCZ administration (Fig. 5) (15, 16) . In the report of VRCZ penetration into pleural fluid (15) T a b l e 1 . VRCZ Co n c e n t r a t i o n s i n P l a s ma a n d P l e u r a l F l u i d (2, 7, 17 
F i g u r e 5 . Ch e s t X-r a y a n d CT , a f t e r d i s c o n t i n u a t i o n o f c h e s t t u b e d r a i n a g e , s h o w c o l l a p s e d l u n g a n d d e c r e a s e d p l e ur a l f l u i d i n t h e l e f t t h o r a c i c c a v i t y .
such as increasing pleural fluid, (1,3)-β-D-glucan, CRP, galactomannan antigen, or anti-Aspergillus antibody, were noted after discontinuation of antifungal therapy during the follow-up period.
Discussion
Here, we described a case of Aspergillus empyema caused by A. fumigatus, successfully treated with a combination of VRCZ and MCFG. We measured the concentration of VRCZ and MCFG in plasma and pleural fluid. Penetration of VRCZ and MCFG into pleural fluid was excellent (Tables 1, 2). Adequate drug penetration into an infection site is crucial for optimal antimicrobial therapy. In general, the pleural surface is thicker and more acidic in patients with empyema. Pleural diffusion of antibiotics is highly variable (14). There are only a few reports regarding the penetration of antifungal agents, such as VRCZ, and AMPH B lipid formulations into pleural fluid
T a b l e 2 . MCF G Co n c e n t r a t i o n s i n P l a s ma a n d P l e u r a l F l u i d that the VRCZ concentration in pleural fluid was higher than its MIC for A. fumigatus. The penetration ratio of VRCZ was 19-75%, which was lower than that previously reported by Stern et al (15
